HOME >> MEDICINE >> NEWS
VELCADE (Bortezomib) receives European marketing authorisation

Brussels, Belgium, {27 April 2004} Ortho Biotech, the biopharmaceutical division of Janssen-Cilag, today announced that the European Commission has issued a positive decision for VELCADE, a new treatment for multiple myeloma, a form of blood cancer. The novel drug is indicated to treat multiple myeloma patients who have received at least two prior therapies and demonstrated disease progression on their last therapy.

VELCADE is a completely new approach to treating multiple myeloma that acts on a unique target in cells called the proteasome.

Multiple myeloma is the second most common blood cancer, representing approximately one percent of all cancers and two percent of all cancer deaths. Worldwide in 2000, there were 73,943 cases of multiple myeloma and 57,370 deaths. In Europe there were approximately 19,000 cases in 2000 and just under 15,000 deaths (1). Only 30 percent of multiple myeloma patients survive longer than five years (2).

"The approval of VELCADE by the European Agency for the Evaluation of Medicinal Products (EMEA) represents a breakthrough in our continued battle against multiple myeloma" said Professor Mario Boccadoro, Professor of Hematology, Director of the Section of Hematology, University of Torino, Italy. "With its new and unique mechanism of action, VELCADE represents a new treatment option for patients".

Clinical results from a phase II study have shown that VELCADE can slow, reverse or halt progression of disease in patients who failed on two or more treatments, potentially helping patients live longer. In a study of 202 patients with relapsed and refractory multiple myeloma and who progressed after initial treatments, 35% responded to VELCADE and 10% had a complete remission. This pivotal study was the basis for an accelerated review of VELCADE by U.S. Food and Drug Administration (FDA) and approval within four months of the New Drug Application submission on 13 May 2003.

"We are deli
'"/>

Contact: Eva Reynolds
eva_reynolds@uk.bm.com
44-20-7831-6262
Burson-Marsteller
28-Apr-2004


Page: 1 2 3

Related medicine news :

1. VELCADE(TM) data confirms long-term survival
2. UIC professor receives international humanitarian award
3. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
4. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
5. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
6. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
7. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
8. American Academy of Neurology program receives Grassroots Award
9. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers
10. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
11. Pfizers antifungal medicine VFEND receives FDA approval

Post Your Comments:
(Date:9/3/2015)... ... September 03, 2015 , ... At Renew Man™, we have seen an ... health care model, where the primary care physician dictates and the patient obeys. Instead, ... educated about their health issues and empowered to choose their own treatment options. , ...
(Date:9/3/2015)... ... ... James Earl Jones will be hosting an upcoming VOICES IN AMERICA segment that ... a segment that discusses why it is important for the workplace to be healthier, ... any working environment. , Employers are out billions of dollars year after year due ...
(Date:9/3/2015)... Aurora, COLO (PRWEB) , ... September 03, 2015 , ... ... from the very beginning of the most recent episode of the hit ABC series ... Kim didn’t fit the image of her industry. She provided herself with the motivation ...
(Date:9/2/2015)... ... ... Sara Bleich, Ph.D., associate professor of health and policy ... recognized scholar on obesity prevention and control, has been selected for the prestigious ... graduate of Garrison Forest School, an all-girls’ independent school in Owings Mills, Md., ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... Military Officers Association of America (MOAA) and Wounded Warrior Project® (WWP), will ... Our Own,” expert panelists will lead interactive discussions on the responsibilities and ...
Breaking Medicine News(10 mins):Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 3Health News:James Earl Jones Hosts a New "Voices In America" Piece on Making the Workplace Healthier 2Health News:New “Extreme Weight Loss” Video Blog from the CU Anschutz Health and Wellness Center: Kim Begins with the End in Mind and Designs a Fashionable Future 2Health News:New “Extreme Weight Loss” Video Blog from the CU Anschutz Health and Wellness Center: Kim Begins with the End in Mind and Designs a Fashionable Future 3Health News:Dr. Sara Bleich, Garrison Forest Graduate, Selected for 2015-16 Class of White House Fellows 2Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 2Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 3
(Date:9/2/2015)...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... of Neurocrine Biosciences, will be presenting at the Baird ... . The live presentation takes place ... The presentation will be webcast and may be accessed ... Listeners are encouraged to visit the website ...
(Date:9/2/2015)... Research and Markets ... Jain PharmaBiotech,s new report "Therapeutic Drug Monitoring ... offering. This report deals with therapeutic ... improving patient care by monitoring drug levels in ... drugs for improving outcome. TDM is viewed as ...
(Date:9/2/2015)... Sept. 2, 2015  MiMedx Group, Inc. (NASDAQ: ... human amniotic tissue and patent-protected processes to develop ... Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic ... inaccurate statements published by the Musculoskeletal Transplant Foundation ... 2015. MTF,s September 1st press release ...
Breaking Medicine Technology:Global Therapeutic Drug Monitoring Technologies, Markets, and Companies Report 2015 - Updated 2015 Analysis with Forecasts to 2024 2MiMedx Corrects A Second Inaccurate MTF Press Release 2MiMedx Corrects A Second Inaccurate MTF Press Release 3
Cached News: